Publications (2)1.17 Total impact
-
Article: LARaLink 2.0: a comprehensive aid to basic and clinical cytogenetic research.
[show abstract] [hide abstract]
ABSTRACT: LARaLink 2.0 (Loci Analysis for Rearrangement Link) is an enabling web technology that permits the rapid retrieval of clinical cytogenetic and molecular data. New data mining capabilities have been incorporated into version 2.0, building upon LARaLink 1.0, to extend the utility of the system for applications in both the clinical and basic sciences. These include access to the Chromosomal Variation in Man database and the GEO database. Together these new resources enhance the user's ability to associate genotype with phenotype to identify potential gene candidates. Unlimited access for researchers exploring disease-gene relationships and for clinicians extending practice in patient care is available at LARaLink.bioinformatics.wayne.edu:8080/ unigene.Genetic Testing 02/2005; 9(4):334-41. · 1.17 Impact Factor -
Article: Genomic rearrangement and disease LARaLINK 2.0: Datamining for clinical cytogenetics
[show abstract] [hide abstract]
ABSTRACT: A growing pool of genomic data is being archived to online public databases. These have the potential to impact both the diagnosis of genetically linked diseases as well as to aid in defining their genesis. The current in-silico tools for cytogenetic analysis have generally been targeted to the academic and industrial communities for use in research into the origins of disease. In comparison, few tools have been developed to integrate the multiple online resources for the clinical setting. We have addressed this deficit through a web-delivered application, LARaLINK 2.0: Loci Analysis for Rearrangements Link version 2.0 http://www.LARaLINK.bioinformatics.wayne.edu:8080/unigene controlled hierarchical vocabulary for mining cDNA and microarray expression data. This tool now provides researchers and clinicians with the means to effectively use cytogenetic data to rapidly assess disease association. The investigator is delivered a defined set of candidate disease genes together with the supporting evidence for their expression and disrupted phenotypes.Applied Mycology and Biotechnology 6:249-275.
